

Purified anti-DYKDDDDK Tag Antibody

Catalog# / Size	637319 / 25 µg 637301 / 200 µg 637302 / 500 µg 637303 / 1 mg 637304 / 5 mg
Clone	L5
Regulatory Status	RUO
Other Names	FLAG tag
Isotype	Rat IgG2a, λ
Description	The DYKDDDDK tag, commonly referred to as Sigma®'s FLAG® Tag, is often used as a protein modification in order to simplify the labeling and detection of proteins. This unique amino acid sequence allows for specific antibody detection in western blotting, immunoprecipitation, and immunostaining techniques. Due to the short sequence, this modification is not likely to affect the structure or function of the modified proteins.

Product Details

Verified Reactivity	DYKDDDDK tag epitope
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	DYKDDDDK-tagged mouse Langerin
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	WB - Quality tested IP, ICC, ELISA, FC, Purification - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by Western blotting . For Western blotting, suggested working dilution(s): Use 5 µg per 5 ml antibody dilution buffer for each mini-gel. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	The L5 clone has been demonstrated to have 2-8 fold better sensitivity in WB than another commonly used antibody clone, M2.
Application References	<ol style="list-style-type: none">1. Park SH, <i>et al.</i> 2008. <i>J Immunol Methods</i>. 331:27.2. Moon SH, <i>et al.</i> 2010. <i>J. Biol Chem</i>. 285:12935. PubMed3. Sasaki M, <i>et al.</i> 2011. <i>J. Biol Chem</i>. 286:39370. PubMed4. Sonder SU, <i>et al.</i> 2012. <i>J Immunol</i>. 188:5906. PubMed5. Jiang Y, <i>et al.</i> 2013. <i>Int Immunol</i>. 25:235. PubMed6. Zuo X, <i>et al.</i> 2014. <i>PLoS One</i>. 9:84748. PubMed7. Toyo-Oak K, <i>et al.</i> 2014. <i>J Neurosci</i>. 34:12168. PubMed
Product Citations	<ol style="list-style-type: none">1. DaRosa PA <i>et al.</i> 2018. <i>Molecular cell</i>. 72(4):753-765 . PubMed2. Mamedov T, <i>et al.</i> 2019. <i>PLoS One</i>. 14:e0213438. PubMed3. Asano Y, <i>et al.</i> 2021. <i>Nat Commun</i>. 12:4372. PubMed4. Zhu C, <i>et al.</i> 2020. <i>Cell Rep</i>. 31:107745. PubMed5. Willcox CR, <i>et al.</i> 2020. <i>Immunity</i>. 51(5):813-825.e4.. PubMed6. Bala Tannan N, <i>et al.</i> 2018. <i>PLoS Genet</i>. 14:e1007153. PubMed7. Chaouat AE, <i>et al.</i> 2021. <i>PLoS Pathog</i>. 17:e1010175. PubMed8. Das A, <i>et al.</i> 2016. <i>J Biol Chem</i>. 291: 6096 - 6110. PubMed

9. Wroblewska A *et al.* 2018. *Cell*. 175(4):1141-1155 . [PubMed](#)
10. Yang M, *et al.* 2020. *Appl Environ Microbiol*. 86:00:00. [PubMed](#)
11. Mamedov T, *et al.* 2017. *PLoS One*. 10.1371/journal.pone.0183589. [PubMed](#)
12. Wang X, *et al.* 2018. *Pathog Dis*. 76:. [PubMed](#)
13. Sundaram A *et al.* 2017. *eLife*. 6 pii: e27187. [PubMed](#)
14. Sánchez-Bellver L, *et al.* 2022. *Int J Mol Sci*. 23:. [PubMed](#)
15. He H, *et al.* 2021. *J Immunother Cancer*. 9:. [PubMed](#)
16. Sims S, *et al.* 2021. *Adv Virol*. 2021:5569844. [PubMed](#)
17. Wen XY, *et al.* 2018. *JCI Insight*. 3:. [PubMed](#)
18. Nabar NR, *et al.* 2022. *Autophagy*. 18:204. [PubMed](#)
19. Bonet-Ponce L, *et al.* 2020. *Sci Adv*. 6:00. [PubMed](#)
20. Ren S, *et al.* 2016. *PLoS One*. 11: 0152721. [PubMed](#)
21. Jiang Y, *et al.* 2013. *Int Immunol*. 25:235. [PubMed](#)
22. Toyooka K, *et al.* 2014. *J Neurosci*. 34:12168. [PubMed](#)
23. Shi Y, *et al.* 2016. *Cell Death Differ*. 10.1038/cdd.2016.110. [PubMed](#)
24. Sønder S, *et al.* 2012. *J Immunol*. 188:5906. [PubMed](#)
25. Velay F, *et al.* 2022. *Plant Methods*. 18:69. [PubMed](#)
26. Adam S, *et al.* 2021. *Nat Cancer*. 2:1357. [PubMed](#)
27. Golec E, *et al.* 2019. *FASEB J*. 33:12425. [PubMed](#)
28. Yin J, *et al.* 2015. *Brain*. 138: 2553-2570. [PubMed](#)
29. Park GY, *et al.* 2020. *Immune Netw*. e43:20. [PubMed](#)
30. Karunakaran MM, *et al.* 2020. *Immunity*. 52:487. [PubMed](#)
31. Zang RX, *et al.* 2022. *ACS Omega*. 7:34378. [PubMed](#)
32. Kim J, *et al.* 2021. *J Cell Biol*. 220:. [PubMed](#)
33. Moon S, *et al.* 2010. *J Biol Chem*. 285:12935. [PubMed](#)
34. Yuan Y, *et al.* 2020. *Nat Commun*. 11:1472. [PubMed](#)
35. Zhang S, *et al.* 2020. *Nat Commun*. 11:1312. [PubMed](#)
36. Okamoto Y, *et al.* 2021. *J Cell Sci*. 134:. [PubMed](#)
37. Fujii T, *et al.* 2021. *Bone Res*. 9:4. [PubMed](#)
38. Zuo X, *et al.* 2014. *PLoS One*. 9:84748. [PubMed](#)
39. Carlevaro G, *et al.* 2019. *Methods Mol Biol*. 1955:135. [PubMed](#)
40. Liu X, *et al.* 2021. *Hum Mol Genet*. 30:30. [PubMed](#)
41. Hu J, *et al.* 2021. *Cell Death Dis*. 12:391. [PubMed](#)
42. Sandhu R, *et al.* 2021. *Proc Natl Acad Sci U S A*. 118:. [PubMed](#)
43. Stroukov W, *et al.* 2019. *Front Genet*. 10:163. [PubMed](#)
44. Cross SH, *et al.* 2020. *PLoS Genet*. 16:e1008583. [PubMed](#)
45. Takahashi K, *et al.* 2020. *Cell Reports*. 31(9):107715. [PubMed](#)
46. Wu G, *et al.* 2021. *Nat Cancer*. 2:1170. [PubMed](#)
47. Xu C, *et al.* 2019. *J Immunol*. 203:2141. [PubMed](#)
48. Driskill JH, *et al.* 2021. *Genes Dev*. 35:495. [PubMed](#)
49. Liu X, *et al.* 2019. *Nat Commun*. 10:3020. [PubMed](#)
50. Mamedov T, *et al.* 2019. *Sci Rep*. 9:9868. [PubMed](#)
51. Figueroa F, *et al.* 2021. *Front Cell Dev Biol*. 9:739445. [PubMed](#)
52. Sharma VP, *et al.* 2021. *Nat Commun*. 12:7300. [PubMed](#)
53. Yang Q, *et al.* 2020. *Elife*. 9:00. [PubMed](#)
54. Torres-Ayuso P, *et al.* 2021. *Cancer Discovery*. 11(6):1411-1423. [PubMed](#)

RRID

AB_2749907 (BioLegend Cat. No. 637319)
 AB_1134266 (BioLegend Cat. No. 637301)
 AB_1134268 (BioLegend Cat. No. 637302)
 AB_1134265 (BioLegend Cat. No. 637303)
 AB_1134267 (BioLegend Cat. No. 637304)

Antigen Details

Biology Area

Cell Biology

Antigen References

1. Einhauer A. 2001. *J. Biochem. Biophys. Methods*. 49:455.
2. Knappik A and Pluckthun A. 1994. *Biotechniques*. 17:754.

Gene ID

NA


Related Protocols

[Western Blotting Protocol](#)

Other Formats

Purified anti-DYKDDDDK Tag, Anti-DYKDDDDK Tag (L5) Affinity Gel, APC anti-DYKDDDDK Tag, PE anti-DYKDDDDK Tag, Direct-Blot™ HRP anti-DYKDDDDK Tag, Alexa Fluor® 594 anti-DYKDDDDK Tag, Alexa Fluor® 647 anti-DYKDDDDK Tag, Alexa Fluor® 488 anti-DYKDDDDK Tag, PE/Cyanine7 anti-DYKDDDDK Tag, Brilliant Violet 421™ anti-DYKDDDDK Tag, PerCP/Cyanine5.5 anti-DYKDDDDK Tag, Ultra-LEAF™ Purified anti-DYKDDDDK Tag, PE/Dazzle™ 594 anti-DYKDDDDK Tag Antibody, TotalSeq™-B1129 anti-DYKDDDDK Tag, TotalSeq™-A1129 anti-DYKDDDDK Tag, TotalSeq™-C1129 anti-DYKDDDDK Tag

Product Data



Cell extracts from untransfected 293T cells (lane 1) or 293T cells transfected with a plasmid encoding DYKDDDDK-tagged protein (lane 2), using anti-DYKDDDDK, clone L5.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587